• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Commentary: Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial.

作者信息

Das Sunit, Sahgal Arjun, Perry James R

机构信息

Division of Neurosurgery and Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada.

Department of Radiation Oncology, Sunnybrook Hospital, University of Toronto, Toronto, ON, Canada.

出版信息

Front Oncol. 2020 Jan 31;10:66. doi: 10.3389/fonc.2020.00066. eCollection 2020.

DOI:10.3389/fonc.2020.00066
PMID:32083011
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7005933/
Abstract
摘要

相似文献

1
Commentary: Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial.评论：洛莫司汀-替莫唑胺联合疗法与标准替莫唑胺疗法治疗新诊断的具有甲基化启动子的胶质母细胞瘤患者（CeTeG/NOA-09）：一项随机、开放标签的3期试验
Front Oncol. 2020 Jan 31;10:66. doi: 10.3389/fonc.2020.00066. eCollection 2020.
2
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial.洛莫司汀-替莫唑胺联合治疗与标准替莫唑胺治疗在甲基化 MGMT 启动子的新诊断胶质母细胞瘤患者中的比较（CeTeG/NOA-09）：一项随机、开放标签、3 期试验。
Lancet. 2019 Feb 16;393(10172):678-688. doi: 10.1016/S0140-6736(18)31791-4. Epub 2019 Feb 14.
3
Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial.替莫唑胺联合洛莫司汀与单独替莫唑胺治疗新诊断、MGMT 甲基化胶质母细胞瘤患者的健康相关生活质量和神经认知功能：一项随机、多中心、开放性、3 期临床试验（CeTeG/NOA-09）。
Lancet Oncol. 2019 Oct;20(10):1444-1453. doi: 10.1016/S1470-2045(19)30502-9. Epub 2019 Sep 2.
4
First multicentric real-life experience with the combination of CCNU and temozolomide in newly diagnosed promoter methylated wildtype glioblastoma.CCNU与替莫唑胺联合用于新诊断的启动子甲基化野生型胶质母细胞瘤的首次多中心真实世界经验。
Neurooncol Adv. 2022 Aug 24;4(1):vdac137. doi: 10.1093/noajnl/vdac137. eCollection 2022 Jan-Dec.
5
Patterns, predictors and prognostic relevance of high-grade hematotoxicity after temozolomide or temozolomide-lomustine in the CeTeG/NOA-09 trial.特莫唑胺或替莫唑胺-洛莫司汀治疗后的高级血液学毒性的模式、预测因素及预后相关性：CeTeG/NOA-09 试验。
J Neurooncol. 2023 Jan;161(1):147-153. doi: 10.1007/s11060-022-04203-4. Epub 2023 Jan 7.
6
Lomustine and temozolomide for newly diagnosed glioblastoma with methylated promoter: Lessons from the CeTeG/NOA-09 trial.洛莫司汀和替莫唑胺用于新诊断的启动子甲基化胶质母细胞瘤：来自CeTeG/NOA-09试验的经验教训。
Transl Cancer Res. 2019 Dec;8(Suppl 6):S589-S591. doi: 10.21037/tcr.2019.06.43.
7
Tumour Treating Fields (TTFields) in combination with lomustine and temozolomide in patients with newly diagnosed glioblastoma.替莫唑胺联合肿瘤电场治疗用于初诊胶质母细胞瘤患者。
J Cancer Res Clin Oncol. 2020 Mar;146(3):787-792. doi: 10.1007/s00432-019-03106-8. Epub 2019 Dec 11.
8
Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide.接受放疗、洛莫司汀联合替莫唑胺治疗的胶质母细胞瘤患者的长期生存情况。
J Clin Oncol. 2009 Mar 10;27(8):1257-61. doi: 10.1200/JCO.2008.19.2195. Epub 2009 Feb 2.
9
Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3.预测新诊断胶质母细胞瘤患者生存的列线图：欧洲癌症研究与治疗组织（EORTC）和加拿大国家癌症研究所（NCIC）试验26981-22981/CE.3的预后因素分析
Lancet Oncol. 2008 Jan;9(1):29-38. doi: 10.1016/S1470-2045(07)70384-4. Epub 2007 Dec 21.
10
Acquired temozolomide resistance in human glioblastoma cell line U251 is caused by mismatch repair deficiency and can be overcome by lomustine.人胶质母细胞瘤细胞系 U251 获得替莫唑胺耐药性是由错配修复缺陷引起的，并用洛莫司汀可以克服。
Clin Transl Oncol. 2018 Apr;20(4):508-516. doi: 10.1007/s12094-017-1743-x. Epub 2017 Aug 20.

引用本文的文献

1
Glutathione peroxidase 4 overexpression induces anomalous subdiffusion and impairs glioblastoma cell growth.谷胱甘肽过氧化物酶4的过表达诱导异常亚扩散并损害胶质母细胞瘤细胞的生长。
J Biol Eng. 2024 Dec 21;18(1):72. doi: 10.1186/s13036-024-00472-x.
2
Postoperative NEOadjuvant TEMozolomide followed by chemoradiotherapy versus upfront chemoradiotherapy for glioblastoma multiforme (NEOTEM) trial: Interim results.多形性胶质母细胞瘤术后新辅助替莫唑胺序贯放化疗与直接放化疗的对比研究（NEOTEM试验）：中期结果
Neurooncol Adv. 2024 Nov 14;6(1):vdae195. doi: 10.1093/noajnl/vdae195. eCollection 2024 Jan-Dec.
3
Precision medicine advancements in glioblastoma: A systematic review.胶质母细胞瘤的精准医学进展：一项系统综述。
Biomedicine (Taipei). 2023 Jun 1;13(2):1-13. doi: 10.37796/2211-8039.1403. eCollection 2023.
4
Emerging therapies for glioblastoma: current state and future directions.胶质母细胞瘤的新兴疗法：现状与未来方向。
J Exp Clin Cancer Res. 2022 Apr 15;41(1):142. doi: 10.1186/s13046-022-02349-7.
5
Combination chemotherapy versus temozolomide for patients with methylated MGMT (m-MGMT) glioblastoma: results of computational biological modeling to predict the magnitude of treatment benefit.替莫唑胺联合化疗与替莫唑胺治疗甲基化 MGMT（m-MGMT）胶质母细胞瘤患者：预测治疗获益程度的计算生物学模型研究结果。
J Neurooncol. 2021 Jul;153(3):393-402. doi: 10.1007/s11060-021-03780-0. Epub 2021 Jun 8.

本文引用的文献

1
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial.洛莫司汀-替莫唑胺联合治疗与标准替莫唑胺治疗在甲基化 MGMT 启动子的新诊断胶质母细胞瘤患者中的比较（CeTeG/NOA-09）：一项随机、开放标签、3 期试验。
Lancet. 2019 Feb 16;393(10172):678-688. doi: 10.1016/S0140-6736(18)31791-4. Epub 2019 Feb 14.
2
MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges.MGMT 启动子甲基化状态检测指导胶质母细胞瘤的治疗：基于新出现的证据和当前的挑战来改进方法。
Neuro Oncol. 2019 Feb 14;21(2):167-178. doi: 10.1093/neuonc/noy132.
3
Chloroethylating nitrosoureas in cancer therapy: DNA damage, repair and cell death signaling.在癌症治疗中使用烷化剂类氮芥：DNA 损伤、修复和细胞死亡信号转导。
Biochim Biophys Acta Rev Cancer. 2017 Aug;1868(1):29-39. doi: 10.1016/j.bbcan.2017.01.004. Epub 2017 Jan 29.
4
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.西仑吉肽联合标准治疗用于伴有 MGMT 启动子甲基化的新诊断胶质母细胞瘤患者（CENTRIC EORTC 26071-22072 研究）：一项多中心、随机、开放标签、3 期临床试验。
Lancet Oncol. 2014 Sep;15(10):1100-8. doi: 10.1016/S1470-2045(14)70379-1. Epub 2014 Aug 19.
5
Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.替莫唑胺对比标准 6 周放疗对比低分割放疗用于 60 岁以上胶质母细胞瘤患者：北欧随机 3 期试验。
Lancet Oncol. 2012 Sep;13(9):916-26. doi: 10.1016/S1470-2045(12)70265-6. Epub 2012 Aug 8.
6
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial.替莫唑胺化疗单独与单独放疗治疗老年恶性星形细胞瘤的比较：NOA-08 随机、3 期试验。
Lancet Oncol. 2012 Jul;13(7):707-15. doi: 10.1016/S1470-2045(12)70164-X. Epub 2012 May 10.
7
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.同步放化疗联合辅助替莫唑胺与单纯放疗对胶质母细胞瘤生存影响的随机III期研究：EORTC-NCIC试验的5年分析
Lancet Oncol. 2009 May;10(5):459-66. doi: 10.1016/S1470-2045(09)70025-7. Epub 2009 Mar 9.
8
Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide.接受放疗、洛莫司汀联合替莫唑胺治疗的胶质母细胞瘤患者的长期生存情况。
J Clin Oncol. 2009 Mar 10;27(8):1257-61. doi: 10.1200/JCO.2008.19.2195. Epub 2009 Feb 2.
9
Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03.洛莫司汀联合替莫唑胺化疗加放疗用于新诊断胶质母细胞瘤的II期试验：UKT-03
J Clin Oncol. 2006 Sep 20;24(27):4412-7. doi: 10.1200/JCO.2006.06.9104.
10
MGMT gene silencing and benefit from temozolomide in glioblastoma.MGMT基因沉默与胶质母细胞瘤对替莫唑胺的获益
N Engl J Med. 2005 Mar 10;352(10):997-1003. doi: 10.1056/NEJMoa043331.